Literature DB >> 8017094

Ligand-specificity of the rat GLP-I receptor recombinantly expressed in Chinese hamster ovary (CHO-) cells.

H C Fehmann1, J Jiang, J Schweinfurth, K Dörsch, M B Wheeler, A E Boyd, B Göke.   

Abstract

Glucagon-like peptide-I (GLP-I) is a potent incretin hormone and is considered as a new therapeutic tool in the treatment of diabetes mellitus. This study was designed to precisely characterize the binding behavior and activation of the recombinant GLP-I receptor against naturally occurring ligands of the glucagon/VIP/secretin peptide hormone family. CHO-cells were stably transfected with a plasmid containing a cDNA encoding for the rat GLP-I receptor. Northern blot analysis with this cDNA showed a single band of 2.7 kb in CHO cells, while in RINm5F cells, three bands of 2.7, 3.4, and 3.6 kb were specifically labelled. In receptor-binding studies 125I-GLP-I was displaced by GLP-I and weakly by PHI and oxyntomodulin but not by helodermin, helospectin I, helospectin II, secretin, VIP, and PACAP-38. Intracellular cAMP generation was stimulated by GLP-I, PHI, and oxyntomodulin. Helodermin, helospectin I, helospectin II, secretin, VIP, and PACAP-38 were not able to displace 125I-GLP-I from its receptor or to stimulate intracellular cAMP production. This data shows that the GLP-I receptor is characterized by a high ligand specificity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017094

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  10 in total

Review 1.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 2.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 3.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

4.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

5.  Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells.

Authors:  H C Fehmann; M Janssen; B Göke
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

6.  Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.

Authors:  Yanan Hou; Stephen A Ernst; Kaeli Heidenreich; John A Williams
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-05       Impact factor: 4.052

Review 7.  Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.

Authors:  Francis S Willard; Kyle W Sloop
Journal:  Exp Diabetes Res       Date:  2012-05-14

8.  Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes.

Authors:  Chia-Hung Lin; Yun-Shien Lee; Yu-Yao Huang; Sheng-Hwu Hsieh; Zih-Syuan Chen; Chi-Neu Tsai
Journal:  J Diabetes Res       Date:  2015-02-15       Impact factor: 4.011

9.  Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.

Authors:  Lili Shi; Ye Ji; Xiaoyan Jiang; Lihong Zhou; Ying Xu; Yanbo Li; Wei Jiang; Ping Meng; Xiaomin Liu
Journal:  Cardiovasc Diabetol       Date:  2015-02-07       Impact factor: 9.951

10.  Methylation status of vault RNA 2-1 promoter is a predictor of glycemic response to glucagon-like peptide-1 analog therapy in type 2 diabetes mellitus.

Authors:  Chia-Hung Lin; Yun-Shien Lee; Yu-Yao Huang; Chi-Neu Tsai
Journal:  BMJ Open Diabetes Res Care       Date:  2021-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.